Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

Among patients with type 2 diabetes and peripheral artery disease or foot ulcers, the use of semaglutide is linked to a ...

If you’ve been taking Ozempic or Wegovy (both of which contain the active ingredient semaglutide), you might wonder, How long ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

The market for generic GLP-1 weight loss drugs in Canada is set to open up, and Hims & Hers is ready to jump in.  | Novo ...

If you’re struggling with your body image this summer, there is still time to reach your image goals. Robert Andrews Laser & Medical Aesthetics is here to help you out this summer.

A new study suggests that eating more protein while taking GLP-1 medications could help prevent muscle loss, a common side effect of weight loss drugs.

Pointing to Ozempic as a paradigm shift, an elite rehab center is experimenting with GLP-1s to tame many forms of addiction.

A new study finds four factors that may make it more likely for some people to experience successful weight loss from using ...

Investing.com -- Hims & Hers CEO Andrew Dudum has shared new information about the company’s terminated partnership with Novo Nordisk (NYSE: NVO ), which ended in June 2025, in an interview with The ...

SAN FRANCISCO -- In order to maximize weight loss, a GLP-1 receptor agonist may be needed both before and after bariatric ...

Women and older adults taking the anti-obesity drug semaglutide may be at higher risk for muscle loss, but higher protein ...